Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Dynavax Technologies Slid 19% in December

By Cory Renauer – Updated Apr 14, 2019 at 8:54PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors worried disappointing vaccine sales won't improve in 2019 sent the stock tumbling.

What happened

Shares of Dynavax Technologies (DVAX 1.66%), a small biopharmaceutical company struggling to launch a new hepatitis B vaccine and develop a new cancer therapy, fell 19% in December, according to data from S&P Global Market Intelligence. It was a quiet month for Dynavax, but a general market panic dragged the Nasdaq Biotechnology Index 11% lower. 

Check out the latest Dynavax Technologies earnings call transcript.

So what 

Dynavax is more sensitive to market pressure than its peers right now because its first drug launch isn't going very well. The FDA approved Heplisav-B in 2017, but sales during the first nine months of 2018 tallied just $2.9 billion.

Person in a suit drawing a downward sloping chart.

Image source: Getty Images.

The company has an experimental new cancer therapy in development that produced impressive tumor response data early on, but mixed results from an ongoing study are making investors nervous.

Now what

Independent drug launches generally don't perform as well as those with big pharma backing, but Hepislav-B is showing signs of life. Sales in October exceeded the entire first nine months of 2018.

Investors probably don't want to let go of these shares until we hear what the CEO has to say about the year ahead on Thursday, Jan. 10, at the J.P. Morgan Healthcare conference.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool recommends Nasdaq. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.